Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BRKR 
Bruker Corporation (BRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/08/2025: BRKR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 18.96% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/08/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.53B USD | Price to earnings Ratio 47.97 | 1Y Target Price 68.42 |
Price to earnings Ratio 47.97 | 1Y Target Price 68.42 | ||
Volume (30-day avg) 2263229 | Beta 1.18 | 52 Weeks Range 34.10 - 90.25 | Updated Date 04/6/2025 |
52 Weeks Range 34.10 - 90.25 | Updated Date 04/6/2025 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 0.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.36% | Operating Margin (TTM) 16.72% |
Management Effectiveness
Return on Assets (TTM) 5.1% | Return on Equity (TTM) 7.05% |
Valuation
Trailing PE 47.97 | Forward PE 14.49 | Enterprise Value 7593070425 | Price to Sales(TTM) 1.74 |
Enterprise Value 7593070425 | Price to Sales(TTM) 1.74 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 17.31 | Shares Outstanding 151704992 | Shares Floating 103186821 |
Shares Outstanding 151704992 | Shares Floating 103186821 | ||
Percent Insiders 31.91 | Percent Institutions 82.67 |
Analyst Ratings
Rating 4.13 | Target Price 73.8 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bruker Corporation
Company Overview
History and Background
Bruker Corporation was founded in 1960 by Gu00fcnther Laukien in Karlsruhe, Germany. Initially focused on developing advanced electromagnets, the company expanded into nuclear magnetic resonance (NMR) and other analytical instruments. Bruker relocated its headquarters to Billerica, Massachusetts, in 2000, solidifying its presence in the U.S. market and continuing its growth through innovation and strategic acquisitions.
Core Business Areas
- Bruker BioSpin Group: Develops, manufactures, and distributes NMR, EPR, and preclinical MRI instruments for life science research, drug discovery, and materials science.
- Bruker Scientific Instruments (BSI): Offers a wide range of analytical and research tools based on technologies such as mass spectrometry, X-ray diffraction, atomic force microscopy, and optical microscopy. These instruments are used in various applications, including materials research, drug development, clinical diagnostics, and food safety.
- Bruker Energy & Supercon Technologies (BEST): Focuses on superconducting materials and technologies used in MRI magnets, fusion research, and particle accelerators.
Leadership and Structure
Bruker is led by President and CEO Frank H. Laukien. The company operates with a decentralized structure, with each business segment having its own management team. The corporate headquarters provides strategic direction, financial oversight, and shared services.
Top Products and Market Share
Key Offerings
- NMR Spectrometers: Bruker is a leading provider of NMR spectrometers used in various fields, including chemistry, biology, and materials science. Competitors include JEOL and Thermo Fisher Scientific. Bruker holds a significant portion of the NMR market. Revenue is included in Bruker Biospin Group.
- Mass Spectrometers: Bruker's mass spectrometers are used for identifying and quantifying molecules in complex samples. They are essential tools in proteomics, metabolomics, and drug discovery. Competitors include Thermo Fisher Scientific and Agilent Technologies. Market share details are proprietary. Revenue is included in Bruker Scientific Instruments (BSI).
- X-Ray Diffraction (XRD): Bruker's XRD instruments are employed to characterize the atomic and molecular structure of materials. Competitors include Rigaku and PANalytical (Spectris). Market share details are proprietary. Revenue is included in Bruker Scientific Instruments (BSI).
Market Dynamics
Industry Overview
The analytical instrument market is driven by advancements in technology, increasing R&D spending, and growing demand for diagnostics and materials research. Key trends include miniaturization, automation, and the integration of data analytics.
Positioning
Bruker is a leading player in the analytical instrument market, known for its innovative technology, high-performance products, and strong customer support. Its competitive advantage lies in its diverse product portfolio, strong brand reputation, and global presence.
Total Addressable Market (TAM)
The total addressable market for analytical instruments is estimated to be in the tens of billions of USD. Bruker is well-positioned to capture a significant share of this market through its diverse product offerings and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Innovative technology
- Global presence
- Experienced management team
Weaknesses
- High product costs
- Dependence on R&D spending
- Exposure to economic cycles
- Integration challenges from acquisitions
Opportunities
- Growing demand for analytical instruments in emerging markets
- Increasing adoption of advanced technologies
- Expansion into new application areas
- Strategic acquisitions
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Changes in regulations
Competitors and Market Share
Key Competitors
- TMO
- A
- WAT
Competitive Landscape
Bruker enjoys a strong competitive position due to its technological innovation and broad product range. However, it faces stiff competition from larger players with greater resources.
Major Acquisitions
Proteome Factory AG
- Year: 2022
- Acquisition Price (USD millions): 28.1
- Strategic Rationale: Expanded Bruker's proteomics capabilities.
Growth Trajectory and Initiatives
Historical Growth: Bruker has experienced steady growth in revenue and earnings over the past decade, fueled by organic growth and strategic acquisitions.
Future Projections: Analysts expect Bruker to continue to grow at a healthy pace in the coming years, driven by increasing demand for its products and services. Growth estimates from analysts should be obtained from financial news sources.
Recent Initiatives: Bruker has recently focused on expanding its presence in emerging markets, investing in new product development, and streamlining its operations.
Summary
Bruker is a strong company with a diverse product portfolio and a leading position in the analytical instrument market. Its technological innovation and global presence are key strengths. However, it faces intense competition and must manage its high product costs and integration challenges from acquisitions.
Similar Companies
A
Agilent Technologies Inc
A
Agilent Technologies Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
KEYS
Keysight Technologies Inc
KEYS
Keysight Technologies Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
WAT
Waters Corporation
WAT
Waters Corporation
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Outlets (Yahoo Finance, Bloomberg)
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bruker Corporation
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2000-08-04 | Chairman, CEO & President Dr. Frank H. Laukien Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 11396 | Website https://www.bruker.com |
Full time employees 11396 | Website https://www.bruker.com | ||
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.